Three benefit groups were created basedon RVOTD-ICD benefit score, which was calculated from VT/VF score (younger age,higher RVOTD, diuretic use, prior non-sustainable VT, prior sustainable VT/VF)and non-arrhythmic mortality scores (older age, renin-angiotensin-aldosteronesystem inhibitors use, diabetes, higher left ventricular end-diastolic diameter,New York Heart Association III/IV, higher N-terminal pro-B-type natriureticpeptide levels). The gene discussed is REN; the disease is diabetes mellitus.